HealthDay News — Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia, according to a study published in JAMA Cardiology.
Marshal B. Elam, MD, PhD, from the Memphis Veterans Affairs Medical Center and University of Tennessee Health Sciences Center, and colleagues examined whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. A total of 4644 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study participants were followed for an additional 5 years, for a total of 9.7 years.
The researchers found that following completion of ACCORD, only 4.3% of study participants continued fenofibrate treatment. Among participants originally randomly assigned to fenofibrate or placebo, high-density lipoprotein (HDL) and triglyceride values rapidly equalized.
During 9.7 years of follow-up, the hazard ratio (HR) for the primary study outcome (composite of fatal and nonfatal myocardial infarction and stroke) among participants originally randomized to fenofibrate vs placebo (HR: 0.93; 95% CI, 0.83-1.05; P =.25) was comparable with that originally seen in ACCORD (HR: 0.92; 95%, 0.79-1.08; P =.32). For participants with dyslipidemia, fenofibrate therapy effectively reduced CVD (HR: 0.73; 95% CI, 0.56-0.95).
“The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol,” the researchers wrote.
Disclosures: Several authors disclosed financial ties to the pharmaceutical industry; several pharmaceutical companies provided study medications, equipment, and supplies during ACCORD.
- Elam MB, Ginsberg HN, Lovato LC, et al; for the ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes [published online December 26, 2016]. JAMA Cardiol. doi:10.1001/jamacardio.2016.4828.